Search

Displaying results 1241 - 1250 of 10000 in total
  1. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    Pegloticase is a porcine recombinant PEGylated uricase indicated for the treatment of chronic gout in adult patients that do not respond to other types of therapies. … [A249980] The PEG group also gives pegloticase a lower potential to induce an immune response.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    FDA in July 2025 for patients who have undergone four or more prior lines. Continued approval in the U.S. is contingent upon verification of clinical benefit in a confirmatory trial. [L53363] … [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the

  3. Drug

    Triclabendazole

    go.drugbank.com/drugs/DB12245
    ApprovedInvestigational

    [FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.

  4. Drug

    Doxercalciferol

    go.drugbank.com/drugs/DB06410
    ApprovedInvestigational

    Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients … Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin

  5. Drug

    Formaldehyde

    go.drugbank.com/drugs/DB03843
    ApprovedVet approved

    In solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative. … A highly reactive aldehyde gas formed by oxidation or incomplete combustion of hydrocarbons.

    Mixtures: British Army Foot PwrCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Olodaterol

    go.drugbank.com/drugs/DB09080
    ApprovedInvestigational

    Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. … Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing.

    Mixtures: Spiolto Respimat Inhalation Solution 2.5mcg/2.5mcg per actuation, SPIOLTO RESPIMAT INHALATION SOLUTION 2.5 microgram/2.5 microgram per actuationCategories: Drugs for Obstructive Airway Diseases
  7. Drug

    Patent Blue

    go.drugbank.com/drugs/DB13967
    ApprovedInvestigational

    [A32573] It is a sodium or calcium salt of diethylammonium hydroxide inner salt. … Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979.[L1113] The isomer isosulphan is used in the United States for the same indications than patent blue.[A32574]

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125] … [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer

    Categories: Compounds used in a research, industrial, or household setting, Protectives Against UV-Radiation for Systemic Use
  9. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection … in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons

    Products: Zinbryta Pen
  10. Drug

    Reserpine

    go.drugbank.com/drugs/DB00206
    ApprovedWithdrawn

    It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. … The FDA withdrew its approval for the use of all oral dosage form drug products containing more than 1 mg of reserpine.[L43942]

    Mixtures: Ser-Ap-Es, Ser-AP-ES TabCategories: Antihypertensive Agents Indicated for Hypertension